High HMGN1 levels drive leukemia in Down syndrome
Nature Genetics
April 21, 2014
A genetic cause of the link between Down syndrome and B cell acute lymphoblastic leukemia (B-ALL) in both mice and human cells is reported in a paper published online this week in Nature Genetics. The study identifies a promising drug target to treat B-ALL in Down syndrome.
People with Down syndrome are at a 20-fold risk of developing a type of B-ALL, an aggressive cancer of the white blood cells. David Weinstock and colleagues found that having three copies of a small region of 31 genes on chromosome 21 was sufficient to drive the cancer. Using a combination of experiments in mice and human cells, they found that increased levels of a specific protein, HMGN1, turns on the group of genes needed for the cancer to spread. The increase in HMGN1 levels was specific to Down syndrome B-ALL, but not other types of ALL.
The authors speculate that drugs that inhibit HMGN1 could prove useful for treating B-ALL in Down syndrome patients.
doi:10.1038/ng.2949
Research highlights
-
Dec 6
Ecology: Wildfire may benefit forest batsScientific Reports
-
Dec 5
Astrophysics: Looking directly at the SunNature
-
Dec 4
Biomedical engineering: Neuron on a chipNature Communications
-
Dec 4
Environment: Levels of lithium in waterways of Seoul assessedNature Communications
-
Dec 3
Prenatal androgen exposure linked with polycystic ovarian syndrome riskNature Medicine
-
Dec 3
Climate Change: Hot temperatures and early childbirthNature Climate Change
